3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
16
Neoplasm Metastasis
2
Endometrial Neoplasms
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Melanoma
1
Locally Advanced (Inoperable) or Metastatic Breast Cancer
1
Liposarcoma
1
Leiomyosarcoma
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
HR+/HER2- Breast Cancer
1
HER2 Negative Breast Cancer
1
Glioma
1
Glioblastoma
1
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
1
Diffuse Intrinsic Pontine Glioma
1
Breast Neoplasms, Male
1
Breast Diseases
1
Brain Neoplasms
1
Astrocytoma
1
Anatomic Stage II Breast Cancer AJCC v8
1
Advanced Breast Cancer
1
Interventions
durvalumab
3
abemaciclib
2
Pemetrexed
2
Fulvestrant
2
Cisplatin
2
Carboplatin
2
ribociclib
1
repotrectinib
1
pembrolizumab
1
palbociclib
1
exemestane
1
elacestrant
1
cemiplimab
1
atezolizumab
1
Tamoxifen
1
STX-478
1
RAD1901
1
Nivolumab
1
Metformin
1
Letrozole
1
Immunotherapy
1
Imlunestrant
1
Drug Therapy
1
Docetaxel
1
Bevacizumab
1
Anastrozole
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
ribociclib
×
30 days
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled